Cytokinetics Inc. (CYTK)

Oncology Corporate Profile

Stock Performance

14.5000
0.2000

3 Month Stock History Chart

HQ Location

280 East Grand Avenue
South San Francisco, CA 94080

Company Description

Cytokinetics is a biotechnology company dedicated to the discovery, development and commercialization of therapeutics. It focuses on small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer.

Website: http://www.cytokinetics.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ispinesib / SB-715992KSP inhibitorVarious cancer typesII
ispinesib / SB-715992KSP inhibitorBreast cancerI
SB-743921KSP inhibitorHodgkin's LymphomaIGlaxoSmithKline
ispinesib / SB-715992KSP inhibitorLeukemiaI
SB-743921KSP inhibitorNon-Hodgkin's Lymphoma (NHL)IGlaxoSmithKline
ispinesib / SB-715992KSP inhibitorPediatric solid tumorI
GSK-923295anti-mitotic kinesin centromere-associated protein E (CENP-E)Various cancer typesIGlaxoSmithKline

View additional information on product candidates here »

Source: http://www.cytokinetics.com

Recent News Headlines

Study Examines Link Between HPV in the Mouth and Risk of Head and Neck Cancers

1/21/2016 11:05 am

(Albert Einstein) Jan 21, 2016 - Researchers at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples’ mouths, they are 22 times more likely than those without HPV-16 to develop a type of head and neck cancer.

Cytokinetics, Amgen Drug Shows Promise In Heart Failure Study

11/9/2015 07:08 pm

(Reuters) Nov 8, 2015 - An experimental heart failure drug being developed by Cytokinetics Inc and Amgen Inc demonstrated several beneficial cardiac function effects in a midstage clinical trial, according to data presented on Sunday.

Centers for Medicare and Medicaid Services Imposes Cuts to Radiation Oncology Clinics That May Limit Patient Access to Care

11/4/2015 11:05 am

(ASTRO) Nov 3, 2015 - The final 2016 Medicare Physician Fee Schedule (MPFS) released Friday by the Centers for Medicare and Medicaid Services (CMS) included cuts to radiation oncology clinics that were slightly less severe than anticipated.

ASCO Updates Guidelines for Antiemetics During Chemo

11/4/2015 11:05 am

(Physician’s Briefing/HealthDay News) Nov 2, 2015 - For patients receiving chemotherapy, the use of the oral combination of netupitant (a neurokinin 1 receptor antagonist) and palonosetron (a 5-hydroxytryptamine-3 receptor antagonist) is beneficial for prevention of acute and delayed nausea and vomiting, according to a focused guideline update published online Nov. 2 in the Journal of Clinical Oncology.

UCLA Researchers Find A Wide Variation In Costs To Treat Low-Risk Prostate Cancer

11/4/2015 11:04 am

(UCLA Health) Nov 2, 2015 - Now, for the first time, UCLA researchers have described cost across an entire care process for low-risk prostate cancer – from the time a patient checks in for his first appointment to his post-treatment follow-up testing - using time-driven activity-based costing.

‘Liquid Biopsy’ Promotes Precision Medicine By Tracking Patient’s Cancer

11/4/2015 11:04 am

(TGen) Nov 4, 2015 - A team of researchers, including scientists from the Translational Genomics Research Institute (TGen), has reported that analyzing circulating tumor DNA (ctDNA) can track how a patient’s cancer evolves and responds to treatment.

Naturally High Oestrogen Levels May Lower Women's Bowel Cancer Risk

11/4/2015 11:04 am

(Cancer Research UK) Nov 4, 2015 - Women with naturally higher levels of the sex hormone oestrogen are more than 50 per cent less likely to develop bowel cancer after their menopause than women with low levels, according to research* presented at the National Cancer Research Institute (NCRI) Cancer Conference this week.

Age at Menopause, Hormone Therapy Linked To BCC Risk

11/4/2015 11:04 am

(Doctors Lounge/HealthDay News) Nov 3, 2015 - Late age at natural menopause and menopausal hormone therapy (MHT) use are associated with increased risk of basal cell carcinoma (BCC), according to a study published online Nov. 2 in the Journal of Clinical Oncology.

Changes Urged To Radiotherapy Practice That Could Save NHS Tens Of Millions Per Year

11/4/2015 11:04 am

(ICR [UK]) Nov 4, 2015 - Changes to practice for prostate cancer radiotherapy could save the NHS tens of millions of pounds per year and reduce side-effects and inconvenience for patients, say the leaders of a major phase III clinical trial.

An Aggressive Treatment for an Aggressive Cancer

11/4/2015 11:04 am

(UNM CCC) Nov 3, 2015 - The trial combines the potent chemotherapy regimen FOLFIRINOX and pinpoint-accurate stereotactic body radiation treatment with an immunotherapy drug called algenpantucel-L from NewLink Genetics.

Chemotherapy-induced Hearing Loss Affects Neurocognition in Pediatric Brain Tumor Survivors

11/4/2015 11:04 am

(Children’s Hospital Los Angeles) Nov 3, 2015 - More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin).

CASI Pharmaceuticals Announces First Patient Dosed In Phase 2 Trial For ENMD-2076 In Fibrolamellar Carcinoma (FLC)

11/4/2015 11:04 am

(CASI Pharmaceuticals) Nov 4, 2015 - CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces the dosing of the first patient in a Phase 2 clinical trial in patients with advanced fibrolamellar carcinoma (FLC) at Memorial Sloan-Kettering Cancer Center.

Halozyme Announces First Clinical Dosing Of Janssen's Daratumumab Using ENHANZE™ Technology

11/4/2015 11:04 am

(CNNMoney) Nov 4, 2015 - Halozyme Therapeutics, Inc. today announced that Janssen Biotech, Inc. has dosed the first patient in a clinical trial evaluating subcutaneous (SC) delivery of daratumumab with Halozyme's proprietary ENHANZE™ technology in multiple myeloma.

Breast Cancer Drug Kadcyla To Remain On NHS After Manufacturer Lowers Price

11/4/2015 11:03 am

(The Guardian [UK]) Nov 4, 2015 - An expensive drug that could prolong the lives of women with advanced breast cancer by at least six months will remain on the list of medicines available on the NHS after the manufacturer agreed to lower the price.

Merck KGaA, Pfizer Widen Development Of Cancer Immunology Drug

11/4/2015 11:03 am

(Reuters) Nov 4, 2015 - Pfizer Inc and Germany's Merck KGaA started the second late-stage drug trial of its avelumab drug against lung cancer, targeting a slice of the growing but crowded cancer immunotherapy field.

Drug Giant Shire Snaps Up Biotech Dyax for $5.9 Billion

11/3/2015 12:01 pm

(TheStreet) Nov 2, 2015 - The Dublin-based pharmaceutical will use the deal to bolster its rare disease drug portfolio, and says it can still afford to bid on larger target Baxalta.

Milestone in HIV as Every-Other-Month Shot Blocks Virus

11/3/2015 12:00 pm

(Bloomberg) Nov 3, 2015 - A long-acting shot to suppress HIV worked as well as a combination of three daily pills, a study from GlaxoSmithKline Plc and Johnson & Johnson found. If borne out in larger trials, such a treatment could revolutionize treatment of the deadly virus.

Gilead’s India Patent Snag May Spur More Low-Cost Sovaldi Copies

1/15/2015 12:00 pm

(Bloomberg) Jan 15, 2015 - The Indian patent office’s rejection of a key patent for Gilead Sciences Inc.’s Hepatitis C treatment Sovaldi may pave the way for more low-cost copies in the country, potentially aiding local companies including Natco Pharma Ltd.

Expert in Immune Responses in Stem Cell Transplantation Joins UPCI

12/17/2014 12:01 pm

(UPMC) Dec 17, 2014 – Warren Shlomchik, M.D. has been named director of stem cell transplantation and cell therapies for the University of Pittsburgh’s Division of Hematology-Oncology and University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter, and UPCI’s scientific director of hematopoietic malignancies.

Cytokinetics Shares Fall as Lou Gehrig’s Drug Fails

4/25/2014 05:16 pm

(Bloomberg) Apr 25, 2014 - Cytokinetics Inc. tumbled by as much as 58 percent after its experimental treatment for Lou Gehrig’s disease didn’t meet its goal in a study, the company’s second drug to fail a trial in seven months.

Cytokinetics Shares Fall as Lou Gehrig’s Drug Fails

4/25/2014 12:01 pm

(Bloomberg) Apr 25, 2014 - Cytokinetics Inc. tumbled by as much as 58 percent after its experimental treatment for Lou Gehrig’s disease didn’t meet its goal in a study, the company’s second drug to fail a trial in seven months.

Amgen, Cytokinetics Report Mixed Results For Heart Failure Drug

9/3/2013 05:32 pm

(The Street) Sep 3, 2013 - An experimental heart failure drug from Amgen and Cytokinetics failed to significantly improve shortness of breath in hospitalized patients, according to results from a mid-stage study announced Tuesday.

Amgen, Cytokinetics Report Mixed Results For Heart Failure Drug

9/3/2013 12:03 pm

(The Street) Sep 3, 2013 - An experimental heart failure drug from Amgen and Cytokinetics failed to significantly improve shortness of breath in hospitalized patients, according to results from a mid-stage study announced Tuesday.

Cytokinetics Says 58 in ALS Trial Got Placebo in Error

7/8/2013 05:10 pm

(Bloomberg) July 8, 2013 - Cytokinetics Inc. is evaluating the costs and timing of a clinical trial for its amyotrophic lateral sclerosis treatment after some patients were given a placebo by mistake. The shares fell as much as 8.8 percent.

Cytokinetics Says 58 in ALS Trial Got Placebo in Error

7/8/2013 12:01 pm

(Bloomberg) July 8, 2013 - Cytokinetics Inc. is evaluating the costs and timing of a clinical trial for its amyotrophic lateral sclerosis treatment after some patients were given a placebo by mistake. The shares fell as much as 8.8 percent.

Astellas Enters $490m Muscle Pact with Cytokinetics

6/26/2013 05:18 pm

(PharmaTimes) June 26, 2013 - Japanese drugmaker Astellas and US biopharmaceutical group Cytokinetics have signed a $490-million pact to work on new drugs for muscle disorders.

Astellas Enters $490m Muscle Pact with Cytokinetics

6/26/2013 12:01 pm

(PharmaTimes) June 26, 2013 - Japanese drugmaker Astellas and US biopharmaceutical group Cytokinetics have signed a $490-million pact to work on new drugs for muscle disorders.

Cytokinetics to Present at 7th Annual JMP Securities Healthcare Conference

7/5/2012 08:00 pm

[Marketwire] - SOUTH SAN FRANCISCO, CA-- - Cytokinetics, Incorporated announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 7th Annual JMP Securities Healthcare Conference ...

Biotechnology Value Fund reports 9.98% passive stake in Cytokinetics

7/4/2012 12:02 am

[at theflyonthewall.com] - Biotechnology Value Fund reports 9.98% passive stake in Cytokinetics